T

Tego Science Inc
KOSDAQ:191420

Watchlist Manager
Tego Science Inc
KOSDAQ:191420
Watchlist
Price: 14 400 KRW 1.55% Market Closed
Market Cap: 116.8B KRW
Section:
 

Relative Value

The Relative Value of one Tego Science Inc stock under the Base Case scenario is 10 431.52 KRW. Compared to the current market price of 14 400 KRW, Tego Science Inc is Overvalued by 28%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

Relative Value
Base Case
10 431.52 KRW
Overvaluation 28%
Relative Value
Price
T
Worst Case
Base Case
Best Case

Valuation Multiples

18.7
P/S
P/S
Price to Sales
18.7
vs History
52
vs Industry
31
Median 3Y
18.4
Median 5Y
19.7
Industry
8.2
More Details
Negative
P/E
P/E
Price to Earnings
N/A
vs History
vs Industry
5
Median 3Y
-37
Median 5Y
40.9
Industry
24.2
More Details
Negative
P/OCF
P/OCF
Price to OCF
N/A
vs History
vs Industry
1
Median 3Y
-101.6
Median 5Y
-49.5
Industry
23
More Details
4.8
P/FCFE
P/FCFE
Price to FCFE
4.8
vs History
55
vs Industry
0
Median 3Y
-50
Median 5Y
5.7
Industry
25.5
More Details
2
P/B
P/B
Price to Book Value
2
vs History
87
vs Industry
34
Median 3Y
2.3
Median 5Y
2.6
Industry
3.3
More Details
12.7
EV/S
EV/S
Enterprise Value to Sales
12.7
vs History
69
vs Industry
30
Median 3Y
13.9
Median 5Y
15.2
Industry
8.6
More Details
18.4
EV/GP
EV/GP
Enterprise Value to Gross Profit
18.4
vs History
68
vs Industry
23
Median 3Y
20.5
Median 5Y
21.3
Industry
10.5
More Details
Negative
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
N/A
vs History
vs Industry
0
Median 3Y
-51.3
Median 5Y
-27.4
Industry
6.1
More Details
Negative
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
N/A
vs History
vs Industry
0
Median 3Y
-49.9
Median 5Y
-44.2
Industry
6.6
More Details
Negative
EV/OCF
EV/OCF
Enterprise Value to OCF
N/A
vs History
vs Industry
2
Median 3Y
-75.6
Median 5Y
-36.4
Industry
8.8
More Details
Negative
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
N/A
vs History
vs Industry
1
Median 3Y
-50.1
Median 5Y
-29.4
Industry
6.8
More Details
2.7
EV/IC
EV/IC
Enterprise Value to IC
2.7
vs History
82
vs Industry
33
Median 3Y
3.4
Median 5Y
4
Industry
5.7
More Details

Multiples Across Competitors

Competitors Multiples
Tego Science Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
KR
Tego Science Inc
KOSDAQ:191420
115.3B KRW 18.7 -35.5 -27.4 -23
IL
Can Fite Biopharma Ltd
TASE:CANF
168.5T ILS 61 044 186.9 -4 192 122 -4 113 755 -4 104 597.9
FR
Pharnext SCA
OTC:PNEXF
6T USD 34 067 817 -161 919.3 -196 621.7 -194 378
US
Abbvie Inc
NYSE:ABBV
382.8B USD 6.4 163 15.9 22.5
US
Amgen Inc
NASDAQ:AMGN
175.6B USD 4.9 25.1 18.1 18.1
US
Gilead Sciences Inc
NASDAQ:GILD
153.4B USD 5.3 18.9 12.7 12.7
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
112.7B USD 9.6 30.7 22.5 23.4
US
Epizyme Inc
F:EPE
94.1B EUR 2 067.9 -527.7 -574.6 -559.3
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
78.8B USD 5.5 17.2 16.4 18.6
AU
CSL Ltd
ASX:CSL
84.9B AUD 3.6 18.9 12.7 15.9
NL
argenx SE
XBRU:ARGX
42.8B EUR 13.8 32.5 55.8 57.3
P/S Multiple
Revenue Growth P/S to Growth
KR
T
Tego Science Inc
KOSDAQ:191420
Average P/S: 8 646 740
18.7
N/A N/A
IL
C
Can Fite Biopharma Ltd
TASE:CANF
61 044 186.9
140%
436 029.9
FR
Pharnext SCA
OTC:PNEXF
34 067 817
N/A N/A
US
Abbvie Inc
NYSE:ABBV
6.4
9%
0.7
US
Amgen Inc
NASDAQ:AMGN
4.9
5%
1
US
Gilead Sciences Inc
NASDAQ:GILD
5.3
4%
1.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
9.6
10%
1
US
E
Epizyme Inc
F:EPE
2 067.9
N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
5.5
6%
0.9
AU
CSL Ltd
ASX:CSL
3.6
5%
0.7
NL
argenx SE
XBRU:ARGX
13.8
49%
0.3
P/E Multiple
Earnings Growth PEG
KR
T
Tego Science Inc
KOSDAQ:191420
Average P/E: 43.8
Negative Multiple: -35.5 		N/A N/A
IL
C
Can Fite Biopharma Ltd
TASE:CANF
Negative Multiple: -4 192 122 N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -161 919.3 N/A N/A
US
Abbvie Inc
NYSE:ABBV
163
89%
1.8
US
Amgen Inc
NASDAQ:AMGN
25.1
45%
0.6
US
Gilead Sciences Inc
NASDAQ:GILD
18.9
190%
0.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
30.7
N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -527.7 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.2
10%
1.7
AU
CSL Ltd
ASX:CSL
18.9
11%
1.7
NL
argenx SE
XBRU:ARGX
32.5
40%
0.8
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
KR
T
Tego Science Inc
KOSDAQ:191420
Average EV/EBITDA: 22
Negative Multiple: -27.4 		N/A N/A
IL
C
Can Fite Biopharma Ltd
TASE:CANF
Negative Multiple: -4 113 755 N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -196 621.7 N/A N/A
US
Abbvie Inc
NYSE:ABBV
15.9
14%
1.1
US
Amgen Inc
NASDAQ:AMGN
18.1
11%
1.6
US
Gilead Sciences Inc
NASDAQ:GILD
12.7
7%
1.8
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
22.5
16%
1.4
US
E
Epizyme Inc
F:EPE
Negative Multiple: -574.6 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
16.4
11%
1.5
AU
CSL Ltd
ASX:CSL
12.7
8%
1.6
NL
argenx SE
XBRU:ARGX
55.8
810%
0.1
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
KR
T
Tego Science Inc
KOSDAQ:191420
Average EV/EBIT: 24.1
Negative Multiple: -23 		N/A N/A
IL
C
Can Fite Biopharma Ltd
TASE:CANF
Negative Multiple: -4 104 597.9 N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -194 378 N/A N/A
US
Abbvie Inc
NYSE:ABBV
22.5
30%
0.8
US
Amgen Inc
NASDAQ:AMGN
18.1
20%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
12.7
12%
1.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
23.4
16%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -559.3 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
18.6
13%
1.4
AU
CSL Ltd
ASX:CSL
15.9
11%
1.4
NL
argenx SE
XBRU:ARGX
57.3
N/A N/A

See Also

Summary
Intrinsic value, competitors valuation, and company profile.
DCF Valuation
Stock valuation using Discount Cash Flow valuation method.
Relative Valuation
Stock valuation using valuation multiples.
Wall Street Estimates
Price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
Stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 309,900+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2026 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.